Group by Gene: Include preclinical: CD Protein Inhibitors Immune Checkpoint Inhibitors Immunotherapy EGFR Tyrosine Kinase Inhibitors Kinase Inhibitors Serine-Threonine Kinase Inhibitors Wnt Signaling Inhibitors PARP Inhibitors | PD1 inhibitor, CTLA4 inhibitor nivolumab + ipilimumab | ALK inhibitor ceritinib | ERK2 inhibitor, ERK1 inhibitor ASN007 | β-catenin antagonist ST316 | PARP1 inhibitor AZD5305 | EGFR inhibitor cetuximab | VEGFR inhibitor, PD1 inhibitor sintilimab + fruquintinib | PD-L1 inhibitor, PD-L2 inhibitor PD-L1 inhibitor + PD-L2 inhibitor |
---|---|---|---|---|---|---|---|---|
ALK fusion | ||||||||
MSI-H/dMMR | ||||||||
KRAS mutation | ||||||||
EWSR1 mutation | ||||||||
PD-L2 overexpression | ||||||||
KRAS G13D | ||||||||
APC mutation | ||||||||
HRD | ||||||||
PIK3CA V955G |